18+ · Research Use Only · Not for Human Consumption
BPC-157: what three decades of research covers.
The most requested recovery peptide has a longer paper trail than most people realize, and clearer limits than most sellers admit. The actual scope of the literature, mapped.
Gastric origins
BPC-157 did not start as a sports-recovery compound. It is a synthetic 15-residue fragment of a protective protein identified in gastric juice, and the earliest literature, dating back to the 1990s, is gastrointestinal: ulcer models, gut-lining protection, inflammatory bowel models in rodents. The name itself, body protection compound, comes from that lineage.
The gastric origin explains two properties that shaped everything after. The peptide is unusually stable for its class, built to survive an environment that destroys most proteins. And its earliest observed effects involved protecting and repairing tissue rather than signaling through one clean receptor pathway, which foreshadowed the sprawling literature that followed.
The soft-tissue turn
From the 2000s onward, the research program widened into the models that made the compound famous: transected tendons, injured ligaments, crushed muscle, damaged nerve tissue, mostly in rats. Across these models the recurring themes are accelerated healing rates, changes in fibroblast migration and activity, and angiogenic signaling, the formation of new capillary supply around damaged tissue. Work on the nitric-oxide system runs through much of it, and a vascular thread examines effects on injured or occluded vessels.
This is the half of the literature recovery researchers cite, and it is why BPC-157 anchors the standard recovery pairing. The companion compound works a different mechanism: TB-500 is studied for actin-driven cell migration, while BPC-157's literature centers on localized angiogenic and healing signaling. The mechanistic split is unpacked in the BPC-157 vs TB-500 comparison.
The limits, stated plainly
Three decades of publications sounds definitive. It is not. The literature is animal-model work, much of it from a concentrated group of laboratories, and no large randomized human trial has been published. Rodent tendon models do not automatically translate to human outcomes, and the field is still waiting for the controlled human data that would settle the question either way. A supplier that tells you otherwise is marketing, not summarizing.
What the record does support is continued research interest, and that is the basis on which the compound is supplied. BPC-157 20mg vials stock at ₱2,240, or ₱2,020 on a first order, double the milligrams of the 10mg size most local listings carry. Stock ships from Metro Manila cold storage, same-day across the metro on verified orders before noon, batch number printed on every label.
Supplied for laboratory research use only. Not for human consumption. Nothing on this page is medical advice.
BPC-157 research questions
Where does BPC-157 come from?
It is a synthetic 15-amino-acid fragment derived from a protective protein identified in gastric juice, which is why the earliest literature is gastrointestinal. The 'BPC' stands for body protection compound.
Is there human trial data on BPC-157?
No large published human trials exist. The literature is overwhelmingly animal-model work, primarily rodent studies, spanning gastric, tendon, ligament, muscle and vascular models. That is the honest state of the evidence.
Why do recovery researchers focus on BPC-157?
The tendon and ligament model literature is the draw: studies in injured-tissue models examining healing rate, fibroblast behavior and angiogenic signaling. It is the most cited compound in soft-tissue recovery research, usually alongside TB-500.
What does BPC-157 cost in the Philippines?
Primara Labs stocks 20mg vials at ₱2,240, or ₱2,020 on a first order, double the 10mg size most listings carry, held in Metro Manila cold storage with same-day metro dispatch before the noon cutoff.